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A B S T R A C T
Objective: To investigate the incidence and predictors of viraemia among individuals on antiretroviral
therapy (ART) in Harare, Zimbabwe.
Methods: Children (0–19 years) and adults (>19 years) starting ART between 2013 and 2015 were
followed for a median of 2.8 and 2.7 years, respectively. The incidence rates of virological failure (VF),
low-level viraemia (LLV), and viral blips were assessed and the predictors of viraemia were determined
using logistic and parametric survival regression analyses.
Results: A total of 630 individuals initiated ART, and 19.7% of children and 5.6% of adults did not achieve
viral suppression by 12 months. Younger age and CD4 count 200 cells/mm3 at baseline were associated
with not being virally suppressed at 12 months in adults. Among those who achieved viral suppression
during the follow-up period, the incidence of VF was higher in children (4.0/100 person-years vs. 0.4/100
person-years in adults; p < 0.001), as was the incidence of LLV (1.9/100 person-years vs. 0.3/100 person-
years in adults; p = 0.03). The incidence rate of blips was 10.9 per 100 person-years in children and 4.0 per
100 person-years in adults.
Conclusions: Children are less likely to reach viral suppression and are at higher risk of viraemia while on
ART than adults. The signiﬁcance of LLV and blips needs further study.
© 2018 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Introduction
Access to antiretroviral therapy (ART) has substantially
increased survival and improved quality of life for HIV-infected
individuals worldwide (Antiretroviral Therapy Cohort C, 2017; De
La Mata et al., 2016). Sustained viral suppression achieved on ART
reduces the risk of immunodeﬁciency, clinical progression, and
HIV transmission (Cohen et al., 2016). According to World Health
Organization (WHO) guidelines, an HIV viral load (VL) of 1000
copies/ml should prompt enhanced counselling and a repeat VL
test within 6 weeks, and two sequential VL measurements of
1000 copies is considered virological failure (VF) and should lead
to regimen change (World Health Organization, 2016).
A proportion of individuals on ART experience low-level
viraemia (LLV) and/or transient viraemia; for example, viral blips
have been reported in up to 40% of HIV-positive individuals on ART
(Grennan et al., 2012; Havlir et al., 2001; Sorstedt et al., 2016). Viral
blips have been shown to be associated with higher HIV pre-
treatment VL and lower CD4 count at the time of ART initiation
(Farmer et al., 2016; Havlir et al., 2001; Sorstedt et al., 2016). There
is some evidence that they may impair CD4 cell recovery and
maintain ongoing low-grade immune activation (Taiwo et al.,
2013; Zoufaly et al., 2014).
Data on detectable viraemia after ART initiation are scarce and
particularly the incidence and signiﬁcance of transient and/or LLV
in low-income settings, where – unlike high-income settings –
* Corresponding author at: Department of Community Medicine, Faculty of
Health Sciences, UiT—The Arctic University of Norway, Hansine Hansens veg 18,
9019 Tromsø, Norway.
E-mail address: evgeniya.sovershaeva@uit.no (E. Sovershaeva).
https://doi.org/10.1016/j.ijid.2018.10.019
1201-9712/© 2018 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
International Journal of Infectious Diseases 78 (2019) 65–71
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
journal home page: www.elsevier .com/ locat e/ i j id
regular VL monitoring is not the norm (Haas et al., 2015). The few
studies that have been conducted in low-income countries have
focused mainly on adults (Kanapathipillai et al., 2014). However,
children are potentially at a higher risk of developing viraemia due
to weight-based dosing, which may lead to variable drug levels,
poor tolerability of drugs, and suboptimal adherence (Easterbrook
et al., 2002; Young et al., 2015). Moreover, psychosocial factors
including dependence on a caretaker and delayed disclosure of HIV
status to the child may put children at higher risk of remaining
viraemic after ART initiation (Lall et al., 2015). Adolescence is a
speciﬁc high-risk period for poor adherence in many chronic
conditions (Taddeo et al., 2008).
In this study, the incidence of and risk factors for detectable
viraemia including VF, LLV, and blips were investigated in a cohort
of HIV-infected children and adults initiated on ART in Harare,
Zimbabwe.
Methods
A retrospective cohort study was conducted using data
collected from patients who attended Newlands Clinic, Harare,
Zimbabwe, a not-for-proﬁt HIV clinic that provides care for
children and adults. ART is provided free of charge according to
national guidelines. Routine 6-monthly VL monitoring is per-
formed (during the study period, this was done using the Roche
COBAS AmpliPrep/COBAS TaqMan48 version 2.0 test; Roche
Molecular Systems, Pleasanton, CA, USA). Adherence and psycho-
social counselling is provided at each clinic visit (at least every 3
months). Adherence is assessed by pill count for each antiretroviral
drug at every clinic visit. In the case of suspected VF (a VL
1000 copies/ml), the patient receives intensiﬁed adherence
counselling for 6 weeks and repeated VL testing. Those with a
VL  1000 copies/ml in two consecutive VL measurements are
considered to have VF and are switched to second-line ART
(protease inhibitor (PI)-based regimen and change of at least one
nucleoside reverse transcriptase inhibitor (NRTI)). Those on
second-line ART who have a VL 1000 copies/ml despite
counselling undergo HIV drug resistance testing and are consid-
ered for third-line ART.
Individuals who were ART-naïve and initiated ART between
August 2013 and August 2015 and who had at least two VL tests
after ART initiation were included in the study. The following data
were extracted: age, sex, date of ART initiation, ART regimen,
adherence, height, weight, clinical history (WHO HIV disease stage,
history of tuberculosis, opportunistic infections, chronic comor-
bidities), and laboratory parameters (VL, CD4 count, haemoglobin)
at the time of ART initiation and during the follow-up period until
September 28, 2017.
Data analysis
All patient data are stored in a secure electronic database. The
data were anonymized prior to analysis. Statistical analyses were
performed in Stata 14 (StataCorp LLC, College Station, TX, USA). The
outcomes were the incidence of VF, LLV, and viral blips. Viral blip
was deﬁned as a VL measurement 50 copies/ml preceded and
followed by a VL below the limit of detection (<50 copies/ml)
(Havlir et al., 2001; Kanapathipillai et al., 2014; Martinez et al.,
2005). LLV was deﬁned as a VL 50 to <1000 copies/ml in at least
two consecutive VL tests. The WHO deﬁnition for VF was used (VL
1000 copies/ml in two consecutive VL measurements) (World
Health Organization, 2016).
The proportion of participants who did not achieve viral
suppression by 12 months of ART (the 12-month cut-off was
chosen to allow for a VL test to conﬁrm suppression at month 12)
was estimated and the factors associated with virological non-
suppression were studied using logistic regression.
The incidence rates of viral blips, LLV, and VF among those who
had achieved viral suppression during the follow-up period and
had at least two VL tests after initial VL suppression were
estimated. Nelson–Aalen cumulative hazard curves were plotted to
evaluate the incidence of VF, LLV, and viral blips after VL
suppression by age at ART initiation (children aged 0–19 years
and adults aged >19 years).
The factors associated with the occurrence of viral blips were
investigated using survival analysis. For the model, participants
were included in the analysis at time 0 (time of ﬁrst suppressed VL
test after ART initiation) and followed until a viral blip occurred, or
for those patients who remained suppressed until the last VL test
available, by the end of the follow-up. Participants who reported
treatment interruption in ART for more than 2 weeks were
excluded from this analysis. Since the estimated cumulative hazard
of blips increased exponentially with time, we ﬁtted the
parametric survival regression with Weibull distribution stratiﬁed
by age group. A value of P (the shape parameter) >1 conﬁrmed that
the hazard of failure (viral blip) increased with time.
Age, sex, body mass index (BMI), stunting (in children only),
pre-treatment VL, CD4 count, anaemia, WHO clinical stage at ART
initiation, history of tuberculosis before ART initiation, chronic
comorbidities (adults only), ART regimen, and average adherence
were investigated as predictors of detectable viraemia. Stunting
was deﬁned as a height-for-age Z-score of <2 (children only).
Height-for-age Z-scores and BMI-for-age Z-scores in children were
calculated using WHO reference standards. Anaemia was deﬁned
according to WHO criteria (haemoglobin <11 g/dl for children <5
years; haemoglobin <11.5 g/dl for children 5–11.99 years; haemo-
globin <12 g/dl for children 12–14.99 years; haemoglobin <12 g/dl
for females aged 15 years; haemoglobin <13 g/dl for males aged
15 years). Adherence was calculated as a percentage of the
number of tablets dispensed at the last visit minus the number of
tablets returned at the current visit divided by number of tablets
that should have been consumed between visits. The average
adherence over the study period was calculated for each
participant. Age, sex, and CD4 count were adjusted for a priori.
All statistical tests were two-tailed and p-values of <0.05 were
considered statistically signiﬁcant.
Ethical approval for the study was obtained from the Newlands
Clinic Research Committee, the Medical Research Council of
Zimbabwe, and Regional Committee for Medical and Health
Research Ethics (Norway).
Results
Of the 725 participants who initiated ART during the study
period, 17 were excluded as they were suppressed at baseline (and
thus may have received ART previously) and 78 were excluded for
having <2 VL measurements available following ART initiation
(Figure 1). The baseline demographic, clinical, and laboratory
characteristics of the remaining 630 participants (127 children and
503 adults) are shown in Table 1. The median follow-up time was
2.8 (interquartile range (IQR) 2.3–3.2) years for children and 2.7
(IQR 1.8–2.8) years for adults. The sex distribution was equal in the
paediatric group (49.6% female vs. 50.4% male), while there were
more adult female than male participants (62.2% female vs. 37.8%
male), consistent with studies in Sub-Saharan Africa, which have
shown higher HIV treatment coverage among women (UNAIDS,
2013). Twenty-one children, all aged below 3 years at ART
initiation, were commenced on PI-based regimens, as per the
national guidelines, which recommend PIs as part of the ﬁrst-line
regimen in children below 3 years. Ten adults initiated treatment
with a PI-based regimen based on clinician judgement, with
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reasons including severe anaemia, Kaposi sarcoma, WHO stage 4,
third trimester of pregnancy, and breastfeeding.
Of the 630 participants, signiﬁcantly more children than adults
did not achieve viral suppression by 12 months post ART initiation
(19.7% children vs. 5.6% adults; p < 0.001). Younger age and CD4
count 200 cells/mm3 at baseline were associated with not
achieving viral suppression in adults (Table 2). Over the follow-
up period, 106 (83.5%) children and 482 (95.8%) adults reached VL
suppression, with the median time to VL suppression being 0.5 (IQR
0.4–1.3) years for children and 0.5 (IQR 0.2–0.8) years for adults.
Table 1
Characteristics of study participants. Results are presented as the number (percentage), or as the median (interquartile range), unless indicated otherwise.
Characteristics Children (n = 127) Adults (n = 503)
Demographic
Male 64 (50.4%) 190 (37.8%)
Age at ART initiation, years 10 (3–15) 37 (31–44)
Stunted at ART initiation (height-for-age Z-score <2) 24 (18.9%)
Underweight at ART initiation (BMI Z-score <2 for children or BMI <18.5 kg/m2 for adults) 13 (10.2%) 40 (8.0%)
Clinical
History of tuberculosis 10 (7.9%) 59 (11.7%)
Prevalence of chronic comorbiditiesa 2 (1.6%) 90 (17.9%)
Opportunistic infectionsb 13 (10.2%) 75 (14.9%)
WHO clinical stage 3 or 4 at ART initiationc 31 (24.8%) 144 (28.9%)
ART regimen at treatment initiation
2NRTI + NNRTI 106 (83.5%) 493 (98.0%)
PI-based 21 (16.5%) 10 (2.0%)
Average adherence to ART by pill-count 98.4% 99.6%
Years on ART 2.8 (2.3–3.2) 2.8 (1.8–2.8)
Laboratory
CD4 count at ART initiation, cells/mm3 341 (137–733) 220 (104–334)
Viral load at ART initiation, log10 copies/mld 4.8 (4.4–5.3) 4.8 (4.3–5.2)
Anaemia at ART initiation 82 (64.6%) 248 (49.4%)
ART, antiretroviral therapy; BMI, body mass index; WHO, World Health Organization; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse
transcriptase inhibitor; PI, protease inhibitor.
a Chronic comorbidities included hypertension, diabetes, or renal failure diagnosed before inclusion in the study.
b After ART initiation, had at least one episode of one of the following: oral candidiasis, necrotizing gingivitis, herpes zoster, histoplasmosis, cryptococcal meningitis,
molluscum contagiosum, genital warts, tonsillitis.
c Data missing for two children and ﬁve adults.
d Data missing for 42 children and 159 adults.
Figure 1. Flow chart of participant recruitment.
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Table 2
Logistic regression analysis of the risk factors for not achieving viral suppression by 12 months of ART.
Characteristic Children (19 years of age) (n =127) Adults (>19 years of age) (n =503)
Unadjusted analysis Adjusted analysisa Unadjusted analysis Adjusted analysisa
OR (95% CI) p-Value OR (95% CI) p-Value OR (95% CI) p-Value OR (95% CI) p-Value
Female 1.69 (0.69–4.11) 0.25 1.71 (0.69–4.19) 0.24 0.59 (0.27–1.26) 0.17 0.72 (0.33–1.60) 0.43
Age at ART initiation (per 1 year older) 1.05 (0.98–1.13) 0.18 1.06 (0.96–1.18) 0.23 0.97 (0.93–1.01) 0.15 0.95 (0.91–1.00) 0.04
Stunted at ART initiation (height-for-age Z-score <2), yes vs. no 0.53 (0.14–1.93) 0.33 – – – – – –
BMI Z-score (children) or BMI kg/m2 (adults) at ART initiation 0.78 (0.57–1.07) 0.12 0.79 (0.56–1.13) 0.21 0.91 (0.84–0.98) 0.01 0.94 (0.87–1.03) 0.22
History of TB, yes vs. no – – – – 1.70 (0.62–4.64) 0.30 0.92 (0.31–2.74) 0.89
Chronic comorbiditiesb, yes vs. no – – – – 0.53 (0.16–1.81) 0.32 0.86 (0.24–3.16) 0.83
WHO clinical stage 3 or 4 at ART initiation, yes vs. no 1.23 (0.46–3.30) 0.68 1.44 (0.51–4.06) 0.49 2.24 (1.04–4.84) 0.04 1.18 (0.50–2.83) 0.70
ART regimen at treatment initiation (Ref. 2NRTI +NNRTI)c 0.64 (0.17–2.36) 0.50 1.06 (0.17–6.72) 0.95 – – – –
Average adherence to ART by pill-count, % 0.88 (0.72–1.07) 0.21 0.85 (0.69–1.05) 0.14 0.97 (0.89–1.06) 0.54 1.00 (0.91–1.09) 0.92
CD4 count at ART initiation, cells/mm3
200 cells/mm3 2.55 (1.02–6.36) 0.04 2.21 (0.78–6.29) 0.14 5.66 (2.11–15.1) 0.001 5.92 (2.18–16.1) <0.001
>200 cells/mm3 Ref. Ref. Ref. Ref.
Viral load at ART initiation, log10 copies/ml 1.15 (0.63–2.11) 0.65 1.48 (0.73–3.00) 0.27 1.78 (1.00–3.18) 0.05 1.26 (0.68–2.33) 0.46
Anaemia at ART initiation, yes vs. no 1.53 (0.58–4.00) 0.38 1.46 (0.55–3.88) 0.45 2.26 (1.00–5.10) 0.05 1.73 (0.72–4.19) 0.22
ART, antiretroviral therapy; OR, odds ratio; CI, conﬁdence interval; BMI, body mass index; TB, tuberculosis; WHO, World Health Organization; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse
transcriptase inhibitor; PI, protease inhibitor.
a Adjusted for CD4 count at ART initiation, age, and sex.
b Chronic comorbidities included hypertension, diabetes, or renal failure diagnosed before inclusion in the study.
c PI-based regimen as the exposure.
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(Figure 2B). VF was more common in children compared to adults
(8.3% vs. 0.9%; p < 0.001). The incidence of VF was 4.0 (95% CI 2.0–
7.9) per 100 person-years in children and 0.4 (95% CI 0.2–1.2) per
100 person-years in adults (Figure 2C). Notably, 2.2% of children
<10 years and 13.7% of those 10 years developed VF (p = 0.05). All
four adults with VF had re-suppression (three following a switch
from a non-nucleoside reverse transcriptase inhibitor (NNRTI)-
based to a PI-based regimen, one remaining on the same NNRTI-
based regimen), while only three children had re-suppression (two
following a switch from an NNRTI-based to a PI-based regimen,
one remaining on the same NNRTI-based regimen) during the
follow-up period.
Four out of 22 children (18.2%) experienced both viral blips and
VF during the follow-up. Blips were followed by VF in two
participants, while blips occurred after VF and re-suppression in
the other two cases. In those participants with blips followed by VF,
the magnitude of blips was low, while in those who had blips after
VF, blips were of medium (200–499 copies/ml) and high
(>500 copies/ml) magnitude. Among two children with blips after
VF, one had re-suppression on the same ART regimen with
adherence counselling, while another had re-suppression after a
switch to a PI-based regimen. Two children with blips followed by
VF remained unsuppressed by the end of follow-up.
Due to low rates of LLV in the study participants after initial VL
suppression, risk factors for only viral blips were investigated in
the survival analysis. The survival analysis included 507 partic-
ipants (94 in the paediatric group and 413 in the adult group). No
baseline characteristics were found to be associated with an
increased risk of viral blips in children or adults (Table 3).
Discussion
Among individuals starting ART, a signiﬁcantly higher propor-
tion of children compared to adults did not achieve viral
suppression by 12 months. Likely reasons include poor tolerability
to antiretroviral drugs, inadequate ART dosing, or suboptimal
adherence (Boerma et al., 2016). This is in line with the ﬁndings of
Jobanputra et al., who showed that being a child or adolescent is
associated with detectable viraemia (Jobanputra et al., 2015). Some
individuals may require longer periods to achieve suppression, as
shown in the present study, where over the follow-up period,
83.5% of children and 95.8% of adults did achieve viral suppression.
One possibility is that perinatally HIV-infected young children tend
to have sustained high VL in the ﬁrst years of life with slow
reduction of peak VL with increasing age (McIntosh et al., 1996).
This potentially could contribute to incomplete initial VL
suppression and a higher risk of viraemia. Yet the present study
results do not support this, as the exclusion of children aged 3
years did not change the rates of viral non-suppression in the
paediatric study group. Lower CD4 count at baseline was
associated with not being suppressed at 12 months in adults, a
ﬁnding consistent with other studies (Anude et al., 2013;
Collaboration of Observational et al., 2008; Mujugira et al.,
2016; Samuel et al., 2014).
This study found a signiﬁcantly higher incidence of viral blips
among children compared to adults. The reported incidence of
blips varies in different populations (Farmer et al., 2016; Grennan
et al., 2012; Havlir et al., 2001; Kanapathipillai et al., 2014; Sorstedt
et al., 2016), largely due to different deﬁnitions and variability of
the assays for VL. We used a common deﬁnition of viral blip, as a
single VL measurement 50 copies/ml preceded and followed by
VL <50 copies/ml (Fung et al., 2012; Ryscavage et al., 2014).
Compared to studies that have used a similar deﬁnition, it was
found that a lower proportion of adults in the present study
experienced blips: 8.3% during 2.1 years of follow-up compared to
18.6–40% followed up from 1.08 to 1.58 years (Havlir et al., 2001; Ta
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Martinez et al., 2005; Sklar et al., 2002). Several studies have
shown that patients on PI regimens are more prone to developing
viral blips (Grennan et al., 2012; Sorstedt et al., 2016). Havlir et al.
(2001) reported a high incidence of blips (40%) in a cohort of
patients who received an unboosted PI-based treatment regimen
in a high-income country. In addition, the median number of VL
measurements was 17 per participant, compared to an average of
six measurements in the present study in which only 2.1% of adults
were receiving a ritonavir-boosted PI-based regimen.
It is likely that more frequent VL testing will increase the
probability of detecting blips, which may explain the discrepancies
between our ﬁndings and those of studies conducted in high-
income settings. However, in a study comparing the incidence of
blips in high-, middle-, and low-income countries, 21% of the
individuals in the ﬁrst category experienced blips, while only 11%
of participants did so in the middle/low income group, despite a
similar ratio of blips to the number of VL measurements across the
settings (Kanapathipillai et al., 2014). HIV plasma RNA measure-
ments are subject to pre-analytic and laboratory errors, variations
in cut-off point, and variations in lower limit of detection among
the different VL assays, which may have an impact on the incidence
of blips (Grennan et al., 2012; Young et al., 2015). Even though good
agreement between the different assays is observed at high VL
levels, there is substantial variability at low VL levels (Ruelle et al.,
2012; Swenson et al., 2014a).
There appear to be limited data on the incidence of viral blips in
children in the low-income setting (Jobanputra et al., 2015; Szubert
et al., 2017). In a retrospective analysis of VL tests among children
who initiated ART in Uganda and Zimbabwe, 46% of children
experienced viral blips (Szubert et al., 2017). This is considerably
higher than the results of the present study, but may be explained
by the use of WHO 2006 criteria for ART initiation, which relied on
clinical and/or immunological assessment and not just the
diagnosis of HIV infection. The majority of studies in low-income
countries have investigated the incidence of any detectable
viraemia in one or two VL measurements. For example, a cross-
sectional study among adolescents with HIV conducted in an urban
setting in Cameroon utilized two consecutive VL measurements to
detect sustained VL suppression (VL < 50 copies/ml in two VL tests)
(Fokam et al., 2017). In that study, 18.6% of participants had a VL
measurement above 50 copies/ml in a single test. Another study
conducted in Ethiopia found detectable viraemia (deﬁned as an
HIV-1 RNA of 41–1000 copies/ml) in a single VL measurement in
13% of HIV-positive children who had received ﬁrst-line ART for a
median of 24 months (Mulu et al., 2014). In a study by Jobanputra
et al., 38% of children aged <10 years and 34% of children aged 10–
19 years had single detectable VL (>100 copies/ml) followed by VL
re-suppression (Jobanputra et al., 2015). Although the results from
these studies are not directly comparable to the present study
ﬁndings, they show that detectable viraemia is common in
paediatric patients. A multicentre cohort study of data on children
with HIV in the UK and Ireland showed that 22% of participants
with sustained viral suppression experienced transient viraemia
(deﬁned as a single VL >50 copies/ml between two VL tests below
50 copies/ml), with an incidence of 12 per 100 person-years,
similar to the ﬁndings in our study (Lee et al., 2007).
The incidence of LLV and VF after reaching VL suppression was
also signiﬁcantly higher in children than in adults. Furthermore, in
the present study, adolescents (those aged 10 years) were more
likely to experience VF compared to younger children, a ﬁnding
that has also been reported by other studies conducted in Africa
(Makadzange et al., 2015). Adolescence is a period of particularly
high risk for poor adherence (Mukui et al., 2016; Nachega et al.,
2009). Taken together, these emphasize the need for investigating
and addressing factors that impede viral suppression among
adolescents.
The rate of VF in children who reached VL suppression is lower
than those reported by other studies (Makadzange et al., 2015;
Salou et al., 2016). A possible reason for the higher VF rates
reported in other studies is the cross-sectional design of studies
and lack of information regarding initial VL suppression prior to
inclusion in the study (Fokam et al., 2017; Salou et al., 2016). Due to
regular VL monitoring and the longitudinal design of our study, it
was possible to distinguish between those who developed VF and
those who never reached suppression. Another explanation for low
VF in our cohort is the high standard of care provided at Newlands
Clinic, with routine VL testing, continuous adherence monitoring
support, and a rapid response with intensiﬁed adherence
counselling and/or ART switch among those who have a non-
suppressed VL (Haas et al., 2015). Routine VL testing, which is not
available as standard of care in many low-income settings, can
detect VF earlier than targeted VL monitoring, i.e., VL testing
prompted by clinical or immunological deterioration.
A number of studies have shown that episodes of LLV and viral
blips are associated with an increased risk of subsequent VF in
adults (Antiretroviral Therapy Cohort C et al., 2015; Grennan et al.,
2012; Laprise et al., 2013; Leierer et al., 2016). While some studies
have suggested that episodes of transient viraemia may result in
the selection of drug-resistant HIV strains, leading to an increased
risk of VF (Clutter et al., 2016; Gonzalez-Serna et al., 2014; Swenson
et al., 2014b), others have found no link between blips and HIV
progression (Havlir et al., 2001; Kanapathipillai et al., 2014; Nettles
et al., 2005). Young et al. found a gradual increase in the risk of VF
with increasing blip magnitude (Young et al., 2015). In another
study, only blips of 500–999 copies/ml magnitude were associated
with the increased risk of viral rebound (Grennan et al., 2012). In
contrast, other studies have shown no evidence of an association
between blips and VF in adults (Kanapathipillai et al., 2014;
Martinez et al., 2005; Sklar et al., 2002). However, these studies
have been conducted largely in adults. In the present study, not
only did children have a higher risk of VF, but they also had a higher
incidence of viral blips as well as LLV, and the signiﬁcance of these
in predicting VF needs further study. Furthermore, careful
virological monitoring is warranted in children.
The strengths of this study are the use of a standardized
deﬁnition for viral blips, regular VL monitoring, availability of
detailed clinical data including adherence data, and good follow-
up rates. The limitations of the study include the relatively small
sample size and low number of blips in each age group, and there
may therefore be inadequate power to detect an association
between the covariates and the incidence of viral blips. Further-
more, the follow-up period was not long enough to investigate
whether blips or LLV increase the risk of subsequent VF. Adherence
may have been over-estimated, as the pill count is not the optimal
measure of adherence.
In conclusion, this study demonstrated that detectable viraemia
is common among children, although its role with regard to long-
term outcomes necessitates further study in low-income settings,
especially where HIV prevalence is high and the availability of VL
monitoring remains limited.
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